MNG256
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_M85CXHDV | high-grade glioma | — | 0.940 |
| 2 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.911 |
| 3 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.908 |
| 4 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.901 |
| 5 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.900 |
| 6 | 53018DE1-9557-4181-A0F2-5200013F1CEA | — | — | 0.900 |
| 7 | 7E198F8E-BBAA-419D-8986-359C109FBE74 | — | — | 0.893 |
| 8 | MDT-AP-1106 | Med | Medulloblastoma | 0.891 |
| 9 | 2F14C141-CE43-4934-BEC9-769A181DB053 | — | — | 0.891 |
| 10 | c174e0ae-4b0a-4170-9122-b7da8ec61eac | — | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 46 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.644 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.638 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.601 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.578 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.501 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.494 | Idelalisib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.442 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.432 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.382 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.379 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.373 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.365 | Remibrutinib | — uncovered |
| COAGULATION | 0.354 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.352 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.344 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.332 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.331 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.286 | Inavolisib | — uncovered |
| HYPOXIA | 0.268 | Idelalisib | — uncovered |